Top Markets
#1 ADO Protocol ADO Protocol +328.21%
#2 GoPlus Security GoPlus Security +53.42%
#3 Starpower Starpower +46.46%
#4 Nockchain Nockchain +36.58%
#5 Tutorial Tutorial +34.27%
#6 Verus Coin Verus Coin +33.47%
#7 The Black Bull The Black Bull +24.82%
#8 GAIB AID GAIB AID +24.67%
#9 Chainflip Chainflip +23.90%
#10 peaq peaq +19.76%
Coin of the day
ADO Protocol ADO Protocol
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Lisata Therapeutics, Inc. Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc.

LSTA
Rangering i aksjer #32451
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on... Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Aksjekurs
$1.11
Markedsverdi
$10.06M
Endring (1 dag)
1.38%
Endring (1 år)
-56.32%
Land
US
Handel Lisata Therapeutics, Inc. (LSTA)

Kategori

Healthcare
P/S-forhold for Lisata Therapeutics, Inc. (LSTA)
P/S-forhold per 2026 TTM: 0
Ifølge Lisata Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Lisata Therapeutics, Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 -
BE